ROS-1 (ROSプロトオンコジーン1) 阻害剤：対象患者集団・競合情勢・市場予測 (～2034年)

当レポートでは、米国、EU4カ国 (ドイツ、フランス、イタリア、スペイン)、英国、日本におけるROS-1 (ROSプロトオンコジーン1) 阻害剤の市場を調査し、市場背景、市場動向、既存薬および新興薬の概要、競合情勢、市場シェア、患者数、市場規模の推移・予測、アンメットメディカルニーズ、市場アクセスと償還の動向などをまとめています。

主なハイライト：

• 2024年のROS-1 NSCLCの市場規模 (治療ライン別) は3億米ドル近くと推定され、米国が最大シェアを占めています。
• ROS-1阻害剤は、非小細胞肺がん (NSCLC)、乳がん、大腸がん (CRC)、卵巣がんなどに有効な治療薬です。
• NSCLCでは30以上のROS-1融合パートナーが同定されており、CD74、EZR、SDC4、SLC34A2が最も一般的です。NCCNやESMOを含む主要なガイドラインは、進行肺腺がん、大細胞がん、特定不能のNSCLCにおけるROS-1融合体の包括的な分子検査を推奨し、進行扁平上皮がんについてはそれを考慮しています。
• ROS-1融合は、CD74のようなパートナー遺伝子を含むことが多く、症例の約1-2%に認められ、喫煙経験のない若年患者に多く認められます。
• 現在のところ、ROS-1を標的とする治療薬は主にNSCLCに対して開発中です。承認されているROS-1陽性NSCLCを標的とする薬剤には、XALKORI (クリゾチニブ、Pfizer)、ROZLYTREK (エントレクチニブ、Roche (Genentech) )、AUGTYRO (レポトレクチニブ、Bristol Myers Squibb) などがあります。
• Pfizer、Bristol Myers Squibb、Genentech、Nuvalent、Nuvation Bioなど数社が、承認済みの新薬も含めてROS-1阻害薬の開発に取り組んでいます。
• 2024年2月、NVL-520は米国FDAより、少なくとも2種類のROS1 TKIの前治療歴のある転移性ROS1陽性NSCLC患者の治療薬として画期的治療薬指定 (BTD) を受けました。
• 2024年12月、米国FDAはNuvation Bioの進行性ROS1陽性NSCLC (ラインアグノスティック) 治療薬DOVBLERON (taletrectinib) の新薬承認申請を受理しました。米国FDAは本申請を優先審査とし、処方薬ユーザーフィー法 (PDUFA) 目標日を2025年6月23日としました。
• ロルラチニブは、ROS-1融合遺伝子陽性NSCLCの治療薬として正式には承認されていません。しかし、National Comprehensive Cancer Network (NCCN) の腫瘍診療ガイドラインでは、チロシンキナーゼ阻害剤 (TKI) による治療歴のあるROS-1融合体陽性NSCLC患者に対する治療選択肢としてロルラチニブが挙げられています。
• 総じて、ROS-1治療領域は、ROS-1部門における認知度の向上と開発により、2025-2034年の予測期間中に大きな変化を経験すると予測されています。

ROS-1阻害剤レポート：洞察

• 標的患者集団
• 治療アプローチ
• パイプライン分析
• 市場規模および動向
• 既存および将来の市場機会

ROS-1阻害剤レポート：主な強み

• 10年間の予測
• 主要7カ国のカバレッジ
• 主な競合薬
• 薬剤の使用量と主な市場予測の前提条件

ROS-1阻害剤レポート：評価

• 現在の治療法
• アンメットニーズ
• パイプライン製品プロファイル
• 市場の魅力
• 定性分析 (SWOT)

目次

第1章 重要な洞察

第2章 レポートイントロダクション

第3章 ROS1阻害剤：市場概要

• 市場シェア (％) の分布：適応症別

第4章 ROS1阻害剤：エグゼクティブサマリー

第5章 ROS1阻害剤：疫学と市場調査手法

第6章 ROS1阻害剤：重要なイベント

第7章 ROS1阻害剤：背景と概要

• 治療、診断、管理、ガイドライン

第8章 主要7カ国におけるROS1阻害剤の疫学と患者人口

• 主な調査結果
• 前提と根拠：主要7カ国
• 主要7カ国における症例数：ROS-1阻害剤適応症別
• 米国
• EU4カ国・英国
• 日本
  • ROS1阻害薬の特定の適応症における総症例数
  • ROS1阻害薬の特定の適応症に対する治療適格患者数
  • ROS1阻害薬の特定の適応症での実際の治療症例数

第9章 上市済み薬

• 主な競合薬
• XALKORI (crizotinib): Pfizer
• ROZLYTREK (entrectinib): Roche (Genentech)
• AUGTYRO (repotrectinib): Bristol Myers Squibb

第10章 新興薬

• 主な競合薬
• DOVBLERON (taletrectinib): Nuvation Bio/Innovent Biologics/Daiichi Sankyo/Nippon Kayaku
• Zidesamtinib (NVL-520): Nuvalent

第11章 ROS1阻害剤：主要7カ国分析

• 主な調査結果
• 市場見通し
• コンジョイント分析
• 主要な市場予測の前提条件
• 主要7カ国の市場規模：適応症別
• 主要7カ国の市場規模：治療薬別
• 米国
• EU4カ国・英国
• 日本
  • 市場規模：適応症別
  • 市場規模：治療薬別

第12章 主要オピニオンリーダーの見解

第13章 ROS1阻害剤：SWOT分析

第14章 ROS1阻害剤：アンメットニーズ

第15章 市場アクセスと償還

• 米国
• EU4カ国・英国
  • ドイツ
  • フランス
  • イタリア
  • スペイン
  • 英国
• 日本

第16章 付録

第17章 DelveInsightのサービス内容

第18章 免責事項

第19章 DelveInsightについて

List of Tables

• Table 1: Target Population in the 7MM (2020-2034)
• Table 2: Marketed Drug Key cross
• Table 3: Product 1, Clinical Trial Description, 2024
• Table 4: Product 2, Clinical Trial Description, 2024
• Table 5: Emerging Drug Key cross
• Table 6: Product 1, Clinical Trial Description, 2024
• Table 7: Product 2, Clinical Trial Description, 2024
• Table 8: Total ROS-1 Market Size in the 7MM (2020-2034)
• Table 9: ROS-1 Market Size by Therapies in the 7MM (2020-2034)
• Table 10: ROS-1 Market Size by Indication in the 7MM (2020-2034)
• Table 11: Total ROS-1 Market Size in the United States (2020-2034)
• Table 12: ROS-1 Market Size by Therapies in the United States (2020-2034)
• Table 13: Total ROS-1 Market Size in EU4 and the UK (2020-2034)
• Table 14: ROS-1 Market Size by Therapies in EU4 and the UK (2020-2034)
• Table 15: Total ROS-1 Market Size in Japan (2020-2034)
• Table 16: ROS-1 Market Size by Therapies in Japan (2020-2034)

List of Figures

• Figure 1: Target Population in the 7MM (2020-2034)
• Figure 2: Total ROS-1 Market Size in the 7MM (2020-2034)
• Figure 3: ROS-1 Market Size by Therapies in the 7MM (2020-2034)
• Figure 4: ROS-1 Market Size by Indication in the 7MM (2020-2034)
• Figure 5: Total ROS-1 Market Size in the United States (2020-2034)
• Figure 6: ROS-1 Market Size by Therapies in the United States (2020-2034)
• Figure 7: Total ROS-1 Market Size in EU4 and the UK (2020-2034)
• Figure 8: ROS-1 Market Size by Therapies in EU4 and the UK (2020-2034)
• Figure 9: Total ROS-1 Market Size in Japan (2020-2034)
• Figure 10: ROS-1 Market Size by Therapies in Japan (2020-2034)

Key Highlights:

• The total market size in the 7MM for ROS-1 NSCLC by line of therapy was estimated to be nearly USD 300 million in 2024, in which the US accounted for the maximum share of the total market.
• ROS-1 inhibitors are effective treatments for non-small cell lung cancer (NSCLC), breast cancer, colorectal cancer (CRC), ovarian cancer, and others.
• More than 30 ROS-1 fusion partners have been identified in NSCLC, with CD74, EZR, SDC4, and SLC34A2 being the most common. Leading guidelines, including those from NCCN and ESMO, recommend comprehensive molecular testing for ROS-1 fusions in advanced lung adenocarcinoma, large cell, unspecified NSCLC, and consider it for advanced squamous cell carcinoma.
• ROS-1 fusions, which often involve partner genes like CD74, are found in approximately 1-2% of cases and are more frequently observed in younger patients who have never smoked.
• As of now ROS-1 targeting therapies are majorly in development for NSCLC. The approved drugs targeting ROS-1 positive NSCLC include XALKORI (crizotinib, Pfizer), ROZLYTREK (entrectinib, Roche (Genentech), AUGTYRO (repotrectinib, Bristol Myers Squibb), and others.
• Several companies, including Pfizer, Bristol Myers Squibb, Genentech, Nuvalent, Nuvation Bio, and others are engaged in the development of ROS-1 inhibitors with a range of approved and emerging drugs.
• In February 2024, NVL-520 received the Breakthrough Therapy Designation (BTD) from the US Food and Drug Administration (FDA) for the treatment of patients with metastatic ROS1-positive NSCLC who previously received at least 2 ROS1 TKIs.
• In December 2024, the US FDA accepted Nuvation Bio's New Drug Application (NDA) for DOVBLERON (taletrectinib) for the treatment of advanced ROS1-positive NSCLC (line agnostic). The US FDA has granted the application Priority Review and assigned a Prescription Drug User Fee Act (PDUFA) goal date of June 23, 2025.
• Lorlatinib is indeed not officially approved for the treatment of ROS-1 fusion-positive NSCLC. However, the National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology list lorlatinib as a treatment option for patients with ROS-1 fusion-positive NSCLC who have been previously treated with a tyrosine kinase inhibitor (TKI).
• In a nutshell, it is estimated that the ROS-1 treatment space will experience significant changes during the forecast period of 2025-2034 due to an increase in awareness and developments in the ROS-1 segment.

DelveInsight's "ROS Proto-oncogene 1 (ROS-1) Inhibitors -Target Population, Competitive Landscape, and Market Forecast-2034" report delivers an in-depth understanding of the ROS-1 inhibitor, historical and Competitive Landscape, and ROS-1 inhibitor market trends in the United States, EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan.

The ROS-1 inhibitor market report provides current treatment practices, emerging drugs, market share of individual therapies, and current and forecasted 7MM ROS-1 inhibitor market size from 2020 to 2034. The report also covers current ROS-1 inhibitor treatment practices/algorithms and unmet medical needs to curate the best opportunities and assess the market's potential.

Geography Covered:

• The United States
• EU4 (Germany, France, Italy, and Spain) and the United Kingdom
• Japan

Study Period: 2020-2034

ROS Proto-oncogene 1 (ROS-1) Inhibitors Understanding

ROS Proto-oncogene 1 (ROS-1) Inhibitor Overview

ROS-1 inhibitors are TKIs that specifically target the ROS-1 protein, which is often activated in certain types of cancers, particularly NSCLC. ROS-1 (Receptor tyrosine kinase) is a pivotal transmembrane receptor protein tyrosine kinase that regulates several cellular processes like apoptosis, survival, differentiation, proliferation, cell migration, and transformation. Other than NSCLC, it plays an important role in different malignancies, including glioblastoma, CRC, gastric adenocarcinoma, inflammatory myofibroblastic tumors, ovarian cancer, and others. ROS-1 inhibitor is a substance that blocks the activity of an abnormal protein called ROS-1 fusion protein, which is found in some types of cancer cells. Blocking the ROS-1 fusion protein may help keep cancer cells that have it from growing and spreading. Some ROS-1 inhibitors are used to treat cancer. They are a type of targeted therapy. All ROS-1 inhibitors are multi-kinase inhibitors that can inhibit Anaplastic Lymphoma Kinase (ALK), Mesenchymal Epithelial Transition (MET), and other kinases in addition to ROS. ROS-1 kinase inhibitors primarily affect the kinase domain of ROS-1.

Seventy-seven Conventional kinases can be classified into DFG-in (active, type I) and DFG-out (inactive, type II) kinases, depending on the domain conformation.

ROS Proto-oncogene 1 Inhibitor Epidemiology

The ROS-1 inhibitors epidemiology chapter in the report provides historical as well as forecasted epidemiology segmented as total cases in selected indications for ROS-1 inhibitors, total eligible patient pool for ROS-1 inhibitors in selected indications, total treated cases in selected indications for ROS-1 inhibitors in the 7MM covering the United States, EU4 (Germany, France, Italy, and Spain), and the United Kingdom, and Japan from 2020 to 2034.

• In 2024, the total number of NSCLC cases related to ROS-1 gene fusions in the US was approximately ~4,100.
• Among the EU4 and the UK, Germany had the highest number of ROS-1 NSCLC cases, while Spain had the lowest number in 2024.
• According to the American Cancer Society (2024), an estimated 152,810 new cases of CRC were reported in 2024, with 81,540 cases in men and 71,270 cases in women in the US.
• As per estimates, total incident cases of ovarian cancer in the 7MM were ~61,400 in 2024.
• In 2024, the American Cancer Society estimates approximately 310,720 new cases of invasive breast cancer among women in the US. Of these, roughly 15-20% will be classified as TNBC.

ROS Proto-oncogene 1 Inhibitor Drug Chapters

The drug chapter segment of the ROS-1 inhibitor reports encloses a detailed analysis of ROS-1 inhibitor-marketed drugs and mid and late-stage pipeline drugs. It also helps understand the ROS-1 inhibitor's clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug and the latest news and press releases.

Marketed Drugs

AUGTYRO (repotrectinib): Bristol Myers Squibb

AUGTYRO is an oral prescription medicine developed by Bristol Myers Squibb. It is a kinase inhibitor indicated for the treatment of adult patients with locally advanced or metastatic ROS-1-positive NSCLC and adult and pediatric patients 11 years of age and older with solid tumors that have a neurotrophic tyrosine receptor kinase (NTRK) gene fusion and are locally advanced or metastatic or where surgical resection is likely to result in severe morbidity or has progressed following treatment or have no satisfactory alternative therapy.

In November 2023, the FDA approved AUGTYRO for the treatment of adult patients with locally advanced or metastatic ROS-1-positive NSCLC. In June 2024, the FDA announced its accelerated approval for the treatment of adult and pediatric patients 12 years of age and older with solid tumors that have an NTRK gene fusion, are locally advanced or metastatic, or where surgical resection is likely to result in severe morbidity, and have progressed following treatment or have no satisfactory alternative therapy. The approval is received based on the trial TRIDENT-1. In September 2024, AUGTYRO was approved in Japan for the treatment of ROS-1 fusion gene-positive unresectable advanced or recurrent NSCLC.

ROZLYTREK (enrectinib): GENENTECH

ROZLYTREK is an oral prescription medicine developed by Genentech. It is used to treat adults with NSCLC that has spread to other parts of the body and is caused by an abnormal ROS-1 gene. It is also used to treat adults and children 1 month of age and older with solid tumors (cancer) that are caused by certain abnormal NTRK genes and have spread or if surgery to remove their cancer is likely to cause severe complications.

ROZLYTREK (entrectinib) was approved for ROS-1-positive metastatic NSCLC by the FDA in August 2019, the European Commission (EC) in August 2020 for treatment-naive patients, and in Japan in February 2020 for unresectable, advanced, or metastatic ROS-1 fusion-positive NSCLC.

Emerging Drugs

DOVBLERON (taletrectinib): Nuvation Bio/Innovent Biologics/Daiichi Sankyo/Nippon Kayaku

Taletrectinib is an oral, potent, central nervous system-active, and selective, next-generation ROS-1 inhibitor specifically designed for the treatment of patients with advanced ROS-1-positive NSCLC. The US FDA previously granted taletrectinib Breakthrough Therapy Designation (BRD) for the treatment of patients with locally advanced or metastatic ROS-1 positive NSCLC who either have or have not previously been treated with ROS-1 TKIs, and Orphan Drug Designation (ODD) for the treatment of patients with ROS-1 positive NSCLC and other NSCLC indications. Nuvation Bio has initiated an Expanded Access Program (EAP) for taletrectinib in the US for the treatment of patients with locally advanced or metastatic ROS-1-positive NSCLC when no comparable or satisfactory alternative therapy options are available.

Zidesamtinib (NVL-520): Nuvalent

Zidesamtinib is a novel brain-penetrant ROS-1-selective inhibitor created to overcome several limitations observed with currently available therapies. Zidesamtinib received BTD from the US FDA for the treatment of patients with ROS-1-positive metastatic NSCLC who have been previously treated with two or more ROS-1 TKIs. The Phase II portion of the ARROS-1 Phase I/II (NCT05118789) clinical trial of zidesamtinib for patients with advanced ROS-1-positive NSCLC and other solid tumors is now enrolling.

In April 2025, Nuvalent announced the publication of a manuscript in Molecular Cancer Therapeutics, a journal of the American Association for Cancer Research, which supports the rational molecular design of zidesamtinib, its novel and selective ROS-1 inhibitor.

Drug Class Insights

The ROS-1 NSCLC current market is mainly dominated by TKIs such as XALKORI at present and is anticipated to be dominated by AUGTYRO, Taletrectinib, and NVL-520 by 2034. XALKORI is a tyrosine kinase receptor inhibitor, targeting the ALK or ROS-1 kinases (proteins), which turn on the ALK or ROS-1 gene, thus preventing the expression of oncogenic fusion proteins from activating gene expression. AUGTYRO is a next-generation TKI known for its efficient ability to cross the blood-brain barrier. Another emerging drug, which is taletrectinib, functions as a comprehensive inhibitor targeting TRK and ROS-1 with selectivity. Taletrectinib has demonstrated activity against the challenging ROS-1 solvent-front mutation G2032R.

ROS Proto-oncogene 1 Inhibitor Market Outlook

The market for ROS-1 inhibitors is expected to grow significantly in the coming years. This is due to the increasing number of patients who are being diagnosed with different types of cancers, the growing awareness of ROS 1 inhibitors, and the increasing number of ROS-1 inhibitors that are under clinical trials and filed for approval by various companies.

ROS-1 inhibitors demonstrate the highest efficacy in treating NSCLC, whether these are established therapies with regulatory approval or emerging treatments. ROS-1 inhibitors have revolutionized the management of NSCLC, representing a pivotal therapeutic approach. Established treatments such as ROZLYTREK and ZYKADIA (off-label) have demonstrated significant efficacy in ROS-1-positive NSCLC, with expanded indications spanning various disease stages. Additionally, experimental drugs like Zidesamtinib (NVL-520) offer potential effects by inhibiting ROS-1, addressing metastatic solid tumors. With ongoing clinical trials and regulatory advancements, the market outlook for ROS-1 inhibitors is promising, fostering continued innovation and progress in prostate cancer therapeutics. This evolution holds the potential to improve patient outcomes and redefine standards of care in NSCLC management globally.

Several key players, including Genentech, Pfizer, Bristol Myers Squibb, Nuvalent, and others, are involved in developing drugs for ROS-1 inhibitors for various indications such as NSCLC, breast cancer, and others. Overall, this is an exciting new class of agents with great potential for development. The maturation of current studies over the next few years will lead to a better understanding of ROS-1 inhibitors and define their role in the therapy of cancer.

ROS Proto-oncogene 1 Inhibitor Drugs Uptake

This section focuses on the uptake rate of potential approved and emerging ROS-1 inhibitors expected to be launched in the market during 2025-2034.

ROS Proto-oncogene 1 Inhibitor Pipeline Development Activities

The report provides insights into different therapeutic candidates in Phase III, Phase II, and Phase I and analyzes key players involved in developing targeted therapeutics.

The presence of numerous drugs under different stages is expected to generate immense opportunity for ROS-1 inhibitors market growth over the forecasted period.

Pipeline Development Activities

The report covers information on collaborations, acquisitions and mergers, licensing, and patent details for ROS-1 inhibitor therapies.

KOL Views

To keep up with current and future market trends, we take Industry Experts' opinions working in the domain through primary research to fill the data gaps and validate our secondary research. Industry experts were contacted for insights on ROS-1 inhibitors' evolving treatment landscape, patient reliance on conventional therapies, patient therapy switching acceptability, drug uptake, along challenges related to accessibility.

DelveInsight's analysts connected with 20+ KOLs to gather insights; however, interviews were conducted with 10+ KOLs in the 7MM. Centers such as Baptist Health Medical Group and others.

Their opinion helps understand and validate current and emerging therapy treatment patterns or ROS-1 inhibitor market trends. This will support the clients in potential upcoming novel treatments by identifying the overall scenario of the market and the unmet needs.

Qualitative Analysis

We perform Qualitative and market Intelligence analysis using various approaches, such as SWOT analysis. In the SWOT analysis, strengths, weaknesses, opportunities, and threats in terms of disease diagnosis, patient awareness, patient burden, competitive landscape, cost-effectiveness, and geographical accessibility of therapies are provided. These pointers are based on the analyst's discretion and assessment of the patient burden, cost analysis, and existing and evolving treatment landscape.

Market Access and Reimbursement

Reimbursement may be referred to as the negotiation of a price between a manufacturer and payer that allows the manufacturer access to the market. It is provided to reduce the high costs and make the essential drugs affordable. Health technology assessment (HTA) plays an important role in reimbursement decision-making and recommending the use of a drug. These recommendations vary widely throughout the seven major markets, even for the same drug.

In the US healthcare system, both Public and Private health insurance coverage are included. Also, Medicare and Medicaid are the largest government-funded programs in the US. The major healthcare programs including Medicare, Medicaid, the Children's Health Insurance Program (CHIP), and the state and federal health insurance marketplaces are overseen by the Centers for Medicare & Medicaid Services (CMS). Other than these, Pharmacy Benefit Managers (PBMs), and third-party organizations that provide services, and educational programs to aid patients are also present.

The report further provides detailed insights on the country-wise accessibility and reimbursement scenarios, cost-effectiveness scenario of approved therapies, programs making accessibility easier and out-of-pocket costs more affordable, insights on patients insured under federal or state government prescription drug programs, etc.

The abstract list is not exhaustive, will be provided in the final report

Key Updates on ROS-1 Inhibitor

• In May 2025, Nuvation Bio announced that new data from a matching-adjusted indirect comparison study evaluating taletrectinib versus entrectinib in ROS-1-positive NSCLC was presented in a poster session at ISPOR 2025.
• In its Q1 2025 presentation, Nuvalent anticipated topline pivotal data for zidesamtinib in the Tyrosine kinase inhibitors (TKIs) pre-treated ROS-1-positive NSCLC population in the first half of 2025, supporting its planned first New Drug Application (NDA) submission by mid-year 2025.
• In January 2025, the European Medicines Agency (EMA) granted a conditional marketing authorization valid throughout Europe for AUGTYRO for the treatment of adult patients with advanced NSCLC.
• In December 2024, Nuvation Bio announced that the US Food and Drug Administration (FDA) has granted the application Priority Review and assigned a Prescription Drug User Fee Act (PDUFA) goal date of June 23, 2025, for DOVBLERON (taletrectinib) for the treatment of patients with advanced ROS-1-positive NSCLC.
• In June 2024, Innovent Biologics and Nuvation Bio announced, at the Annual Meeting of ASCO 2024, data from the pivotal Phase II TRUST-I study of its investigational taletrectinib. Tumors shrank in 91% of taletrectinib-treated patients with advanced ROS-1-positive NSCLC who were ROS-1 TKI-naive and 52% of those who were ROS-1 TKI-pretreated in the study.

Scope of the Report:

• The report covers a segment of key events, an executive summary, and a descriptive overview of the ROS-1 inhibitor, explaining its mechanism, and therapies (current and emerging).
• Comprehensive insight into the competitive landscape, and forecasts, the future growth potential of treatment rate, drug uptake, and drug information have been provided.
• Additionally, an all-inclusive account of the current and emerging therapies and the elaborative profiles of late-stage and prominent therapies will impact the current landscape.
• A detailed review of the ROS-1 inhibitor market, historical and forecasted market size, market share by therapies, detailed assumptions, and rationale behind our approach is included in the report, covering the 7MM drug outreach.
• The report provides an edge while developing business strategies, by understanding trends, through SWOT analysis, expert insights/KOL views, and treatment preferences that help shape and drive the 7MM ROS-1 inhibitor market.

ROS-1 Inhibitor Report Insights

• ROS-1 inhibitors Targeted Patient Pool
• Therapeutic Approaches
• ROS-1 Inhibitor Pipeline Analysis
• ROS-1 Inhibitor Market Size and Trends
• Existing and future Market Opportunity

ROS-1 Inhibitor Report Key Strengths

• Ten years Forecast
• The 7MM Coverage
• Key Cross Competition
• Drugs Uptake and Key Market Forecast Assumptions

ROS-1 Inhibitor Report Assessment

• Current Treatment Practices
• Unmet Needs
• Pipeline Product Profiles
• Market Attractiveness
• Qualitative Analysis (SWOT)

Key Questions:

• What was the ROS-1 inhibitor total market size, the market size by therapies, market share (%) distribution, and what would it look like in 2034? What are the contributing factors for this growth?
• Which drug is going to be the largest contributor in 2034?
• Which is the most lucrative market for ROS-1 inhibitors?
• What are the pricing variations among different geographies for approved therapies?
• How the reimbursement landscape has for ROS-1 inhibitors evolved since the first one was approved? Do patients have any access issues that are driven by reimbursement decisions?
• What are the risks, burdens, and unmet needs of treatment with ROS-1 inhibitors? What will be the growth opportunities across the 7MM for the patient population of ROS-1 inhibitors?
• What are the key factors hampering the growth of the ROS-1 inhibitor market?
• What are the indications for which recent novel therapies and technologies have been developed to overcome the limitations of existing treatments?
• What key designations have been granted to the therapies for ROS-1 inhibitors?
• What is the cost burden of approved therapies on the patient?
• Patient acceptability in terms of preferred therapy options as per real-world scenarios?
• What are the country-specific accessibility issues of expensive, recently approved therapies?

Reasons to buy:

• The report will help develop business strategies by understanding the latest trends and changing dynamics driving the ROS-1 inhibitor market.
• Understand the existing market opportunities in varying geographies and the growth potential over the coming years.
• Distribution of historical and current patient share based on real-world prescription data along with reported sales of approved products in the US, EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan.
• Identifying strong upcoming players in the market will help devise strategies to help get ahead of competitors.
• Detailed analysis and ranking of indication-wise current and emerging therapies under the conjoint analysis section to provide visibility around leading indications.
• Highlights of Access and Reimbursement policies of approved therapies, barriers to accessibility of expensive off-label therapies, and patient assistance programs.
• To understand Key Opinion Leaders' perspectives around the accessibility, acceptability, and compliance-related challenges of existing treatment to overcome barriers in the future.
• Detailed insights on the unmet needs of the existing market so that the upcoming players can strengthen their development and launch strategy.

Table of Contents

1. Key Insights

2. Report Introduction

3. ROS Proto-oncogene 1 Inhibitor Market Overview at a Glance

• 3.1. Market Share (%) Distribution of ROS Proto-oncogene 1 Inhibitor by Indication in 2024
• 3.2. Market Share (%) Distribution of ROS Proto-oncogene 1 Inhibitor by Indication in 2034
• 3.3. Market Share (%) Distribution of ROS Proto-oncogene 1 Inhibitor by Therapies in 2024
• 3.4. Market Share (%) Distribution of ROS Proto-oncogene 1 Inhibitor by Therapies in 2034

4. Executive Summary of ROS Proto-oncogene 1 Inhibitor

5. Epidemiology and Market Methodology of ROS Proto-oncogene 1 Inhibitor

6. Key Events of ROS Proto-oncogene 1 Inhibitor

7. Background and Overview of ROS Proto-oncogene 1 Inhibitor

• 7.1. Introduction
• 7.2. Treatment, Diagnosis, Management and Guidelines

8. Epidemiology and Patient Population of ROS Proto-oncogene 1 Inhibitor in 7MM

• 8.1. Key Findings
• 8.2. Assumptions and Rationale: The 7MM
• 8.3. Total Cases in Selected Indications for ROS-1 Inhibitors in the 7MM
• 8.4. The United States
  • 8.4.1. Total Cases in Selected Indications for ROS-1 Inhibitors in the United States
  • 8.4.2. Total Eligible Patient Pool for ROS-1 Inhibitors in Selected Indications in the United States
  • 8.4.3. Total Treated Cases in Selected Indications for ROS-1 Inhibitors in the United States
• 8.5. EU4 and the UK
  • 8.5.1. Total Cases in Selected Indications for ROS-1 Inhibitors in EU4 and the UK
  • 8.5.2. Total Eligible Patient Pool for ROS-1 Inhibitors in Selected Indications in EU4 and the UK
  • 8.5.3. Total Treated Cases in Selected Indications for ROS-1 Inhibitors in EU4 and the UK
• 8.6. Japan
  • 8.6.1. Total Cases in Selected Indications for ROS-1 Inhibitors in Japan
  • 8.6.2. Total Eligible Patient Pool for ROS-1 Inhibitors in Selected Indications in Japan
  • 8.6.3. Total Treated Cases in Selected Indications for ROS-1 Inhibitors in Japan

9. Marketed Drugs

• 9.1. Key Cross Competition
• 9.2. XALKORI (crizotinib): Pfizer
  • 9.2.1. Product Description
  • 9.2.2. Regulatory Milestones
  • 9.2.3. Other Developmental Activities
  • 9.2.4. Clinical Development
    • 9.2.4.1. Clinical Trials Information
  • 9.2.5. Safety and Efficacy
• 9.3. ROZLYTREK (entrectinib): Roche (Genentech)
  • 9.3.1. Product Description
  • 9.3.2. Regulatory Milestones
  • 9.3.3. Other Developmental Activities
  • 9.3.4. Clinical Development
    • 9.3.4.1. Clinical Trials Information
  • 9.3.5. Safety and Efficacy
• 9.4. AUGTYRO (repotrectinib): Bristol Myers Squibb
  • 9.4.1. Product Description
  • 9.4.2. Regulatory Milestones
  • 9.4.3. Other Developmental Activities
  • 9.4.4. Clinical Development
    • 9.4.4.1. Clinical Trials Information
  • 9.4.5. Safety and Efficacy

10. Emerging Therapies of ROS Proto-oncogene 1 Inhibitor

• 10.1. Key Cross Competition
• 10.2. DOVBLERON (taletrectinib): Nuvation Bio/Innovent Biologics/Daiichi Sankyo/Nippon Kayaku
  • 10.2.1. Product Description
  • 10.2.2. Other Developmental Activities
  • 10.2.3. Clinical Development
    • 10.2.3.1. Clinical Trials Information
  • 10.2.4. Safety and Efficacy
• 10.3. Zidesamtinib (NVL-520): Nuvalent
  • 10.3.1. Product Description
  • 10.3.2. Other Developmental Activities
  • 10.3.3. Clinical Development
    • 10.3.3.1. Clinical Trials Information
  • 10.3.4. Safety and Efficacy

11. ROS Proto-oncogene 1 Inhibitor: 7MM Analysis

• 11.1. Key Findings
• 11.2. Market Outlook
• 11.3. Conjoint Analysis
• 11.4. Key Market Forecast Assumptions
  • 11.4.1. Cost Assumptions and Rebate
  • 11.4.2. Pricing Trends
  • 11.4.3. Analogue Assessment
  • 11.4.4. Launch Year and Therapy Uptake
• 11.5. Market Size of ROS-1 Inhibitors by Indications in the 7MM
• 11.6. Market Size by Therapies in the 7MM
• 11.7. The United States
  • 11.7.1. Market Size of ROS-1 Inhibitors by Indications in the United States
  • 11.7.2. Market Size by Therapies in the United States
• 11.8. EU4 and the UK
  • 11.8.1. Market Size of ROS-1 Inhibitors by Indications in EU4 and the UK
  • 11.8.2. Market Size by Therapies in EU4 and the UK
• 11.9. Japan
  • 11.9.1. Market Size of ROS-1 Inhibitors by Indications in Japan
  • 11.9.2. Market Size by Therapies in Japan

12. Key Opinion Leaders' Views

13. SWOT Analysis of ROS Proto-oncogene 1 Inhibitor

14. Unmet Needs of ROS Proto-oncogene 1 Inhibitor

15. Market Access and Reimbursement

• 15.1. The United States
  • 15.1.1. Centre for Medicare and Medicaid Services (CMS)
• 15.2. In EU4 and the UK
  • 15.2.1. Germany
  • 15.2.2. France
  • 15.2.3. Italy
  • 15.2.4. Spain
  • 15.2.5. The United Kingdom
• 15.3. Japan
  • 15.3.1. MHLW
• 15.4. Market Access and Reimbursement for ROS Proto-oncogene 1 Inhibitor

16. Appendix

• 16.1. Bibliography
• 16.2. Report Methodology

17. DelveInsight Capabilities

18. Disclaimer

19. About DelveInsight